Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Approval would help the company in its head-to-head market battle with main rival Novo Nordisk in the GLP-1 category, whose semaglutide ... their six-minute walking distance test at one year ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...

CHICAGO — Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, according to data from the STRIDE trial presented at the American ...